Gilead Sciences
California-based Gilead is a biopharmaceutical firm best known for its hepatitis C cures Sovaldi and Harvoni, though it's been making headlines more recently due to its experimental coronavirus treatment remdesivir.
Gilead Sciences/AP Images
Company Information
As of 5/23/2022
Country
U.S.
Headquarters
Foster City, Calif.
Industry
Pharmaceuticals
CEO
Daniel P. O'Day
Website
Company Type
Public
Ticker
GILD
Revenues ($M)
$27,305
Profits ($M)
$6,225
Market Value ($M)
$74,656.5
Employees
14,400
Market value as of March 31, 2022.
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)
493
EPS % Change (from 2020)
4830%
EPS % Change (5 year annual rate)
-13.1%
EPS % Change (10 year annual rate)
10.8%
Total Return
Total Return to Investors (2021)
29.8%
Total Return to Investors (5 year, annualized)
4%
Total Return to Investors (10 year, annualized)
16%
Key Financials (Last Fiscal Year)
($ Millions)
% change
Revenues ($M)
-
10%
Profits ($M)
-
-97.7%
Assets ($M)
$68,407
-
Total Stockholder Equity ($M)
$18,202
-
Profit Ratios
Profit as % of Revenues
0.5%
Profits as % of Assets
0.2%
Profits as % of Stockholder Equity
0.7%
Company Information
Impact Segment
-
Sector
-
Industry
-
CEO
-
Website
-
Employees
-
Company Type
-
Revenues ($M) (Last Fiscal Year)
-
Profits ($M) (Last Fiscal Year)
-
Market Value ($M)
-
Company Info
Industry
-
Location
-
Industry Ranking
-
Previous Industry Ranking
-
Previous Top 50 Ranking
-
Website
-
Overall Score
-
Key Attributes of Reputation
Innovation
-
People Management
-
Use of Corporate Assets
-
Social Responsibility
-
Quality of Management
-
Financial Soundness
-
Long-Term Investment Value
-
Quality of Products/Services
-
Global Competitiveness
-
Revenue, Net Income
Revenue past four quarters ($M)
-
Net Income past four quarters ($M)
-
Growth Rates and Ranks
Revenue 3 Yr Growth Rank
-
Revenue 3 Yr Annual Growth Rate
-
EPS 3 Yr Growth Rank
-
EPS 3 Yr Annual Growth Rate
-
Total Return 3 Yr Rank
-
Total Return 3 Yr Annual Rate
-
Beat S&P 500 (9.6%)
-
P/E Ratio
-
Lists ranking Gilead Sciences
Latest news for Gilead Sciences
- Health
In patient with long-term COVID-19, coronavirus mutated to resist antiviral RemdesivirNovember 11, 2021, 9:03 AM UTC - Conferences
Gilead’s remdesivir is now used to treat half of hospitalized COVID patientsApril 28, 2021, 8:40 PM UTC